Cell and gene therapies
-
CSL strikes world-first access deal
- 28 Jun 2024
Pay-for-performance pricing for Hemgenix evidence of innovative payment models needed to address uncertainty and deliver access.
Read more -
Aussie company joins mRNA alliance
- 29 May 2024
Noxopharm joins a global mRNA alliance with an impressive line-up of members, although one big name is missing from the list.
Read more -
The new class Aussies don’t trust
- 05 Apr 2024
2024 Edelman Trust Barometer identifies serious trust deficit for a class that offers the greatest promise for human health this century.
Read more -
MSAC may delay big PBAC outcomes
- 05 Apr 2024
The other HTA committee may prove crucial to new therapies securing public funding, while a gene therapy has struggled to find a path.
Read more -
Excitement and frustration on horizon
- 25 Mar 2024
‘Here we sit at the dawn of molecular medicine,’ said Prof John Rasko at the start of a day highlighting innovation and system challenges.
Read more -
CAR T, AMR focus of horizon event
- 22 Mar 2024
Second horizon scanning event attracts 250 delegates to discuss disruptive innovation, with some usual suspects on the agenda.
Read more -
MSAC ticks one CAR T, defers another
- 23 Feb 2024
Janssen secures a ‘yes, but’ MSAC response as Gilead strengthens its lead with an important recommendation and expanded people focus.
Read more -
Three firsts on track for July MSAC
- 05 Feb 2024
Funding details of BioMarin’s gene therapy revealed along with insights into AstraZeneca and Astellas’ new targeted cancer therapies.
Read more